Registered Distributor for FlowFlex® Rapid Antigen Tests in the UK
TestCliq.com is a Registered Reseller of FlowFlex® Rapid Antigen Test kits in the UK. FlowFlex is one of a few products approved for home testing and only requires a swipe from the front of the nose for an accurate result.
At present, rapid COIVD-19 antigen testing is being rolled out on a wide scale by the UK Government to aid the mass-testing effort. The FlowFlex Covid-19 Antigen Test has been Evaluated and Validated by the UK’s MHRA/DHSC: 1 of only 3 tests approved for use by schools, hospitals, and the army. The FlowFlex Antigen test kit is also used by the NHS in the UK. Read more
The worlds most advanced Covid-19 test kit with 98.8% accuracy
Making antigen rapid testing affordable, convenient and reliable.
The FlowFlex® Rapid Lateral Flow Antigen Test Kit uses the latest patented technology to detect proteins, ensuring that it can detect new strains of the COVID-19 virus, which is imperative as new strains develop overtime, making FlowFlex a long term solution.
It is estimated that 1 in 3 people with Covid-19 do not have symptoms but can still infect others.
- MHRA registered and approved for home use
- CE registered and ISO certified
- FDA authorised
- U.K. Government validated at Public Health England, Porton Down Laboratories
Home Use Approval
- Full “home test” approved in the UK & EU
- Individually packaged with unique QR codes
- Report test results to NHS from home
How it works
FlowFlex SARS-CoV-2 Antigen Self-Test Nasal Available in packages of 1, 5, and 25 tests
- Nasal only test 98.8% accuracy
- Approved for fit to fly
- Accepted as UK 2 day tests
- Detects new virus variants 2-year shelf life
- Next working day delivery
- Emergency same day courier
- Bulk orders available
- Multiple shipment locations
Report Test Results
You should report your positive, negative or void results to the NHS.
Recording all test results helps scientists spot new virus outbreaks and advise how to respond. If people only report a positive result, case levels look higher than they really are.
So even if your result is negative or void, you’ll make sure NHS information stays accurate.
You need the QR code, or the ID number under it to report your result.
Acon Laboratories, Inc is a large global diagnostics company based in the US with manufacturing facilities in the US, China and Mexico. The factory in China has been inspected and approved by the FDA.
It is very important for us to understand exactly where these tests are made and by whom to ensure consistency of quality and supply.
These test kits are fully approved for home self testing!
Acon, one of the professional in-vitro diagnostic products manufacturers, has announced that its FlowFlex SARS-CoV-2 Antigen Rapid Test has been given the CE approval for self-testing. The CE certificate is issued by TUV SUD (CEO123) and validated from 14th of May 2021 until 26th of May 2024.
The Medicines and Healthcare Products Regulatory Agency (MHRA) is the competent authority or regulatory body in the UK.
They do not approve tests on an individual basis but do allow manufacturers to put a CE mark on products that meet a target product profile set by the MHRA. This target product profile contains criteria that tests and test kits should meet.
The Acon Flowflex Rapid AntiGen test kit meets all of the target profile provided by the MHRA.
Approved through phase 3 testing!
Since its establishment in August 2020, the joint PHE Porton
Down and University of Oxford SARS-CoV-2 lateral flow antigen test validation cell has evaluated over 140 lateral flow devices that have been referred by the Department of Health and Social Care (DHSC).
Approximately 30% of the tests that were referred for validation met the standards for phase 2 validation, which are set out in the protocol. PHE Porton Down subsequently performed phase 3 testing to assess whether the lateral flow devices that passed phase 2 displayed performance characteristics desirable for mass population, community-based testing. The desirable performance characteristics are:
very high specificity
very high sensitivity against viral loads
See results here – https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/outcome-of-the-evaluation-of-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens-lateral-flow-devices
The Flowflex tests detect moderate to high viral loads. Patients will have moderate to high viral loads about 3 days before symptoms start until between 7 and 10 days after symptoms start. In this window lateral flow tests, such as the Acon Flowflex tests are very effective.
A positive test should be repeated using a RT-PCR test for confirmation and entry into the national test and trace system. A negative test simply reflects a point in time, showing you do not have active COVID-19 today.
This is difficult to advise as regulatory advice differs. Some bodies advise testing twice a week, or perhaps every Monday in a standard five day week. Other guidance suggests testing every day.
The SARS-CoV-2 Antigen Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection the nucleocapsid protein antigen from SARS-CoV-2 in nasal swab specimens directly from individuals who are suspected of COVID-19 by their healthcare provider within the first seven days of the onset of symptoms.
The SARS-CoV-2 Antigen Rapid Test is a qualitative membrane based chromatographic immunoassay for the qualitative detection of the nucleocapsid protein antigen from SARS-CoV-2 in human nasal swab specimens.
When specimens are processed and added to the test cassette, SARS-CoV-2 antigens, if present in the specimen, will react with the anti-SARS-CoV-2 antibody-coated particles, which have been pre-coated on the test strip. The mixture then migrates upward on the membrane by capillary action. The antigen-conjugate complexes migrate across the test strip to the reaction area and are captured by a line of antibody bound on the membrane. Test results are interpreted visually at 15 minutes based on the presence or absence of visually colored lines.
Results are for the identification of SARS-CoV-2 nucleocapsid antigen. This antigen is generally detectable in upper respiratory samples during the acute phase of infection. Positive results indicate the presence of viral antigens, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status. Positive results do not rule out bacterial infection or co-infection with other viruses. The agent detected may not be the definite cause of disease.
Negative results from patients more than seven days post symptom onset should be treated as presumptive and confirmed with a molecular assay, if necessary, for patient management. Negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions. Negative results should be considered in the context of a patient’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19.